by Admin | Apr 13, 2026 | Explainers
FDA’s AEMS pages include a public dashboard and a standing page for new safety information or potential signals of serious risks. FDA also maintains a 2026 Safety and Availability Communications page for biologics and a long-running Drug Safety Communications hub. The...
by Admin | Apr 13, 2026 | Regulatory Updates
EMA published meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) for 10–12 March 2026 and noted that the committee meeting was followed by EMA Veterinary Medicines Info Day 2026 on 12–13 March 2026, covering scientific, legislative, and...
by Admin | Apr 13, 2026 | AI & Digital PV
EMA’s upcoming events page lists European Shortages Monitoring Platform (ESMP) training on readable IDs and general updates for industry on 14 April 2026. EMA also describes ESMP as the platform through which marketing authorisation holders and national competent...
by Admin | Apr 13, 2026 | Regulatory Updates
EMA’s March 2026 additional monitoring update says Anktiva was added to the list as a new active substance, new biological, and conditionally authorised product. EMA’s published list also records products removed from the list in the same update cycle. For PV readers,...
by Admin | Apr 13, 2026 | Safety Signals
MHRA says Bio Products Laboratory Limited is recalling one batch of Human Rabies Immunoglobulin 500 IU solution for injection after a stability failure caused a reduction in potency. The agency says the action is intended to prevent any potential reduction in clinical...
